SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 12/4/2016 11:45:56 AM - Followers: 60 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
GALT News: Amended Statement of Changes in Beneficial Ownership (4/a) 11/18/2016 05:13:55 PM
GALT News: Amended Statement of Changes in Beneficial Ownership (4/a) 11/18/2016 05:11:24 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 11/15/2016 03:42:30 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 11/15/2016 03:37:11 PM
GALT News: Current Report Filing (8-k) 11/10/2016 08:00:09 AM
PostSubject
#2610   Galectins Twitter following continues to increase and while rickyricks 12/04/16 11:45:56 AM
#2609   New CEO Perspective, good stuff gss2003 12/01/16 08:57:46 AM
#2608   The Galectin-3 might work in Atopic dermatitis, and Inoviorulez 11/29/16 07:37:14 PM
#2607   I would think the partner would influence these things. gss2003 11/29/16 02:29:14 PM
#2606   Atopic Dermatitis is basically a less severe form Chess Master 11/29/16 02:17:23 PM
#2605   I completely agree with your insightful analysis of biotech2010 11/29/16 12:18:29 PM
#2604   How big is the severe atopic dermatitis market gss2003 11/29/16 12:16:56 PM
#2603   Lets distill down to the root of what Chess Master 11/29/16 10:38:29 AM
#2602   I don't think I could have echoed your Chess Master 11/29/16 10:16:05 AM
#2601   Thanks for your non-abrasive writing on the current JERZYATP1 11/27/16 08:27:16 PM
#2600   No idea. I am buying a bunch if gss2003 11/27/16 11:21:46 AM
#2599   No offense but patients in the NASH FX Inoviorulez 11/27/16 10:39:40 AM
#2598   Cellceutix did a Phase 2 POC testing Prurisol thefamilyman 11/26/16 07:37:06 PM
#2597   Exciting time for Galectin. Will 2017 deliver rickyricks 11/26/16 01:41:12 PM
#2596   You keep making these accusations that I have biotech2010 11/23/16 02:53:07 PM
#2595   and soon. Darwinian 11/22/16 02:55:33 PM
#2594   The last paragraph is encouraging, hopefully they identify gss2003 11/22/16 12:16:42 PM
#2593   Thanks for explaining your background.It impresses and is JERZYATP1 11/21/16 07:49:08 PM
#2592   I have been a long time shareholder, but Adi2 11/18/16 02:26:33 PM
#2591   I'm not commenting on what the share price biotech2010 11/18/16 01:29:37 PM
#2590   My simple thought is this: gss2003 11/18/16 09:11:26 AM
#2589   We'll have to agree to disagree on this. biotech2010 11/18/16 12:17:54 AM
#2588   In my opinion altho you have previously shown JERZYATP1 11/17/16 09:36:08 PM
#2587   A. I was answering the prior post biotech2010 11/17/16 11:04:10 AM
#2586   GALT posted a couple summary slides yesterday on gss2003 11/17/16 08:59:03 AM
#2585   I don't follow. They are exploring a partnership gss2003 11/17/16 06:36:00 AM
#2584   Throwing stuff up on the wall to see biotech2010 11/16/16 06:20:49 PM
#2583   And they are trying anything that might give Adi2 11/15/16 02:16:53 PM
#2582   maybe, but who cares, at least it has gss2003 11/15/16 11:22:41 AM
#2581   "Who ..... is running this company, Elmer Fudd?" sunspotter 11/15/16 11:22:35 AM
#2580   I was thinking Daffy Duck but Elmer Fudd thefamilyman 11/14/16 08:44:24 PM
#2579   That's no excuse, it's a reactionary move that biotech2010 11/14/16 07:11:19 PM
#2578   I think it changed course for two reasons jmh0602 11/14/16 07:00:07 PM
#2577   In August they announce they are ending work biotech2010 11/14/16 06:14:36 PM
#2576   * * $GALT Video Chart 11-10-16 * * ClayTrader 11/10/16 05:09:12 PM
#2575   certainly after they announce an actual partnership for this gss2003 11/10/16 11:12:46 AM
#2574   +$1 today shurtha2000 11/10/16 09:32:13 AM
#2573   Saw this in the release this AM, I gss2003 11/08/16 10:31:57 AM
#2572   It looks like GILD's Simtuzumab failed, but they gss2003 11/02/16 03:21:00 PM
#2571   My fear is that they have underestimated the thefamilyman 10/27/16 08:06:17 PM
#2570   The new presentation, besides burying the FX trial biotech2010 10/24/16 09:21:28 PM
#2569   New Corporate Presentation, likely what they'll use for gss2003 10/24/16 03:53:00 PM
#2567   It matters for how much dilution is necessary gss2003 10/23/16 11:29:18 AM
#2566   Does it really matter if the stock price rickyricks 10/22/16 01:18:30 PM
#2565   Several months to compile blood data on 30 biotech2010 10/22/16 11:04:46 AM
#2564   In my exchanges with the company they are gss2003 10/20/16 12:00:07 PM
#2563   What blood work? biotech2010 10/20/16 11:55:15 AM
#2562   I''m curious, if the bloodwork from the FX gss2003 10/20/16 11:51:04 AM
#2561   There is supposed to be a correlation between biotech2010 10/20/16 11:39:41 AM
#2560   I agree, but shouldn't the blood improvements correlate gss2003 10/20/16 10:30:53 AM
PostSubject